Ratio of observed to expected major adverse events (MAE) among patients undergoing congenital cardiac catheterization, risk-adjusted using the Catheterization for Congenital Heart Disease Adjustment for Risk Method II (CHARM II).
This measure captures the proportion of ischemic stroke patients prescribed antithrombotic therapy at hospital discharge.
This measure captures the proportion of ischemic stroke patients who had antithrombotic therapy administered by end of hospital day two (with the day of arrival being day 1).
This measure captures the proportion of ischemic or hemorrhagic stroke patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given on the day of or the day after hospital admission.
This measure captures the proportion of ischemic stroke patients with atrial fibrillation/flutter who are prescribed anticoagulation therapy at hospital discharge.
This measure captures the proportion of ischemic stroke patients who are prescribed a statin medication at hospital discharge.
This measure captures the proportion of ischemic or hemorrhagic stroke patients with documentation that they or their caregivers were given stroke education materials.
This measure captures the proportion of ischemic or hemorrhagic stroke patients assessed for or who received rehabilitation services during the hospital stay.
This measure captures the proportion of ischemic or hemorrhagic stroke patients assessed for or who received rehabilitation services during the hospital stay.
The number per 1,000 livebirths of <1500g infants delivered at hospitals not appropriate for that size infant.